Search

everythinglearnresearchcommunity

for

Search:↓

More prostate biopsies increase the chance of finding cancers that may not need treatment.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Male pattern baldness may predict prostate cancer risk.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.